Brief: Epic Sciences, Fulgent Genetics Collaborate To Deliver Definembc Results For Metastatic Breast Cancer Patients
24/02/2022 14:22
Feb 24 (Reuters) - Fulgent Genetics Inc FLGT.O :
* EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER
DEFINEMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
Source text for Eikon: ID:nPn4Lh0gna
Further company coverage: FLGT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Fulgent Genetics
See all newsU.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary
Fulgent Genetics Q2 revenue rises 20% sequentially, sees billing system transition delay
Brief: Fulgent Genetics Q2 Revenue USD 85.389 Million
Fulgent Genetics Inc expected to post a loss of 46 cents a share - Earnings Preview